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Abstract
Background: Early detection of chronic kidney disease (CKD) is sub-optimal among the general
population and among high risk patients. The prevalence and impact of major CKD risk factors,
diabetes (DM) and hypertension (HTN), on CKD documentation among managed care populations
have not been previously reported. We examined this issue in a Kaiser Permanente Georgia (KPG)
CKD cohort.
Methods: KPG enrollees were included in the CKD cohort if they had eGFRs between 60 and 365
days apart that were <90 ml/min during 1999-2006. The current analysis is restricted to
participants with eGFR 10-59 ml/min/1.73 m2. CKD documentation was defined as a presenting
diagnosis of CKD by a primary care physician or nephrologist using ICD-9 event codes. The
association between CKD documentation and DM and HTN were assessed with multivariate
logistic regression models.
Results: Of the 50,438 subjects within the overall KPG CKD cohort, 20% (N = 10,266) were
eligible for inclusion in the current analysis. Overall, CKD diagnosis documentation was low; only
14.4% of subjects had an event-based CKD diagnosis at baseline. Gender and types 2 diabetes
interacted on CKD documentation. The prevalence of CKD documentation increased with the
presence of hypertension and/or type 2 diabetes, but type 2 diabetes had a lower effect on CKD
documentation. In multivariate analysis, significant predictors of CKD documentation were eGFR,
hypertension, type 2 diabetes, congestive heart failure, peripheral artery disease, statin use, age and
gender. CKD documentation was lower among women than similarly affected men.
Conclusion: Among patients with an eGFR 10-59, documentation of CKD diagnosis by primary
and subspecialty providers is low within a managed care patient cohort. Gender disparities in CKD
documentation observed in the general population were also present among KPG CKD enrollees.
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Background
The prevalence of chronic kidney disease (CKD) is
increasing in the United States [1,2] and is associated with
an increased risk of cardiovascular events, end-stage renal
disease (ESRD) and mortality [3-5]. Early identification
and appropriate care of CKD patients may delays progres-
sion to ESRD and decreases mortality, morbidities, and
cost [6,7]. Yet, the level of CKD awareness is low in both
the general U.S. population (24%) and among high risk
patients (less than 10% among individuals with Stage 3
CKD) [8,9].
The National Kidney Foundation's Kidney Disease Out-
come Quality Initiative (KDOQI) evidence-based clinical
practice guidelines for CKD recommend periodic screen-
ing of high risk individuals for CKD [10]. Specifically, this
entails a clinical evaluation (eg. assessment of symptoms,
risk factors, medical history, family history), measure-
ment of blood pressure, and laboratory evaluation (eg.
serum creatinine, protein-to-creatinine ratio, imaging of
the kidneys).
Despite these recommendations, there is evidence from
national population surveys that high risk patients are
often not screened for CKD and that the presence of CKD
may go unidentified [8,11]. Moreover, CKD identification
by health care providers within health maintenance
organizations have not been fully examined, and predic-
tors of provider awareness of CKD in a high risk patient
population have not been reported.
While CKD documentation may not wholly reflect the
provider's understanding of the individual patient's clini-
cal status, incorporation of this information into clinical
decision systems supported by claims data is important.
This can be illustrated by the recent Centers for Medicare
and Medicaid Services (CMS) contract awarded to Medi-
care Quality Improvement Organizations (QIO) in ten
states in August of 2008 to reduce disparities in the early
detection and care of diabetic CKD among Medicare ben-
eficiaries [12]. A fundamental feature of the chronic dis-
ease model is using ongoing surveillance information,
such as claims data, to develop CKD quality of care reports
for providers and identify opportunities to improve care
[13]. If these claims-based data are systematically biased
or inaccurate due to incomplete documentation then one
can anticipate marked inefficiencies in this and similar
efforts to reduce the burden of CKD.
The aims of the present study were to explore these issues
by examining the prevalence of a documented CKD diag-
nosis in high risk diabetic and hypertensive patients by
primary and subspecialty providers in a health mainte-
nance organization and to determine the nature and mag-
nitude of predictors of CKD documentation.
Methods
Cohort determination
Kaiser Permanente Georgia is a managed care organiza-
tion that serves racially (40% African Americans) and eth-
nically diverse patients in the state of Georgia and
provides health care for approximately 275,000 people in
2007. Kaiser Permanente Georgia uses electronic medical
records for collecting pharmacy and laboratory informa-
tion, hospitalization records, and outpatient diagnoses.
Each member is assigned a unique identification number
and all encounters and claims related to a given enrollee
include that unique identification number and the date of
service.
The KPG Chronic Kidney Disease cohort includes mem-
bers of Kaiser Permanente Georgia who were identified
between January 1, 1999 through January 1, 2006 with an
estimated glomerular filtration rate (eGFR) measure <90
ml/min/1.73 m2. Patients who had at least 2 estimated
glomerular filtration rate (eGFR) measures <90 ml/min/
1.73 m2, when measured at least 60 and no more than
365 days apart, were included in this study. The date of
the first GFR measure was used as the baseline date of
entry into the cohort. The Institutional Review Board of
Kaiser Permanente Georgia and Emory University
approved this study.
Assessment of eGFR, CKD, and other covariates
The KPG Chronic Kidney Disease dataset includes infor-
mation on age, gender, health care providers (such as pri-
mary care physician or specialist), medications and
laboratory measures (such as eGFR). A member was
defined as having diabetes mellitus if (s)he had an HbA1c
measurement  ≥ 7.0% or any of the following criteria
within a 12 month period: 1) 2 or more primary care visits
with an ICD-9 diagnosis code of 250.xx; 2) 2 or more dis-
pensings of an oral hypoglycemic, insulin, or blood glu-
cose testing strips; or 3) 1 primary care visit with an ICD-
9 diagnosis code of 250.xx and 1 dispensing of an oral
hypoglycemic, insulin, or blood glucose testing strips. A
member was defined as having hypertension if (s)he had
blood pressure measured at ≥ 140 SBP or ≥ 90 DBP on a
primary care visit or any of the following criteria within a
12 month period: 1) 2 or more primary care visits with an
ICD-9 diagnosis code of 401.xx; or 2) 1 primary care visit
with an ICD-9 diagnosis code of 401.xx and at least 1 dis-
pensing of a diuretic, ACE inhibitors (ACEI) or angi-
otensin receptor blockers, beta-blocker, or calcium
channel blocker in the previous 12-month period. Health
care providers included primary care departments (family
medicine, internal medicine, obstetrics/gynecology,
urgent care/after hours) and sub-specialty departments
(cardiology, endocrinology, nephrology, renal dialysis,
hospitalizations). Medication claims data were obtained
from the pharmacy dataset that included National DrugBMC Nephrology 2009, 10:25 http://www.biomedcentral.com/1471-2369/10/25
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Codes, prescription date, quantity, days supply, and fill
number. Drugs were then coded and grouped appropri-
ately using the standardized Unified Medical language
System (UMLS) [14]. Laboratory test claims required
identifying and pulling specific laboratory test codes, the
accompanying laboratory test results, as well as the test
date. Notably, creatinine tests and results were reported
uniformly and eGFR computed. GFR was estimated using
the four variables formula from the modification of diet
in renal disease study (MDRD) [15].
Because race was missing on 65% of the members, we
used a single imputation method based on census-based
measures of race. Residential street addresses were geoco-
ded to the census block data from the 2000 U.S. Census.
A variable for neighborhood-level percent African-Ameri-
can race was created. The race term in the MDRD formula
was then calibrated for percent African-American race. For
example, the 1.1212 factor for African Americans in the
MDRD formula was adjusted according to the proportion
of African Americans (pAA) in the Census block using the
formula: 1+(0.212*pAA).
CKD diagnosis documentation was defined by an in-
patient or out-patient diagnosis of CKD by primary care or
subspecialty physician (both internal Kaiser physicians
and external contracted physicians were included). CKD
was defined using International Classification of Diseases, 9th
Revision, Clinical Modification (ICD-9-CM) codes from
event encounters. The list of ICD-9 codes used is provided
in Additional Table 1 [Additional file 1 - STable 1]. To
minimize misclassification on CKD status, the current
analysis was restricted to members with an eGFR 10-59
ml/min/1.73 m2. Members with a diagnosis of end-stage
kidney disease were also excluded.
Statistical analysis
Univariate analyses were conducted using Chi-square tests
and student unpaired independent t tests. Baseline charac-
teristics evaluated include those previously reported to be
important variables predicting CKD incidence and out-
comes. Age and eGFR were evaluated as continuous varia-
bles, whereas all other variables were dichotomized.
Estimated GFR was also categorized by 10-point sub-cate-
gories (i.e. eGFR 10-19, 20-29, 30-39, 40-49, 50-59 ml/
min/1.73 m2). Continuous variables are reported as mean
± SD. Odds ratios and 95% confidence intervals were
reported for both diabetes status and CKD identification.
Univariate and multivariable logistic regression models
were constructed to examine factors associated with CKD
identification. Variables significant at the 5% level from
the univariate analyses were included in the logistic
regression model. Independent variables were retained in
multivariate model unless P > 0.05, or if their inclusion
resulted in a change of 10% or more in the estimate of the
main effect. All test were two-tailed and statistical signifi-
cance was set at P < 0.05. We assessed the potential effect
modification of independent variables on the association
of diabetes status and CKD documentation by performing
tests of statistical interaction with a significance level set at
P < 0.10. All analyses were performed using SAS version
9.1.3 (SAS Institute, Cary, NC, USA).
Results
Study population and baseline characteristics
Of the 50,438 members in the KPG Chronic Kidney Dis-
ease dataset, 40,172 were excluded because they had an
eGFR ≥ 60 (N = 39,955), less than 10 ml/min/1.73 m2 (N
= 33), or had a diagnosis of ESRD (n = 184). One fifth of
the cohort (N = 10,266) were eligible for the current anal-
ysis (Figure 1). Baseline characteristics of the cohort and
the distribution by diabetes status are detailed in Table 1.
The mean (SD) age of members was 63 years and mean
(SD) eGFR was 48 ml/min/1.73 m2. Males constituted
40% of the population and 57% of members had an eGFR
between 50 and 59 ml/min/1.73 m2. At the time of enroll-
ment hypertension was present for 77%, 24% had diabe-
tes, 13% had coronary artery disease, 7% had congestive
heart failure, 5% had peripheral artery disease and 2%
had cerebrovascular disease. ACEI and statin medication
prescription use were similar (14%). Although all partici-
pants had CKD, twelve percent were prescribed a non-ster-
oidal anti-inflammatory medication.
Diabetic subjects were more likely to be older than non-
diabetics (63.50 ± 11.63 vs. 62.92 ± 13.96, p = 0.0386),
and have a lower mean eGFR than non-diabetics (46.0 vs
49.6 ml/min/1.73 m2, p < .0001). The trend for increasing
odds of being diabetic with decreasing eGFR was also sig-
nificant (1.00 (ref) for eGFR 50-59; 1.29 (1.16-1.44) for
eGFR 40-49; 1.80 (1.57- 2.07) for eGFR 30-49; 2.27 (1.86-
2.78) for eGFR 20-39, and 3.13 (2.36- 4.15) for eGFR 10-
19; P for trend < .0001).
Diabetic participants were 4-fold more likely to have
hypertension (P < .0001), and were more than 3-fold
more likely to have peripheral artery disease (P < .0001).
Diabetic subjects were 70% more likely to have coronary
artery disease (P < .0001), two-fold more likely to have
congestive heart failure (P < .0001)) and 92% more likely
to have cerebrovascular disease (P < .0001) compared to
non-diabetic patients. Significant differences were also
found regarding the use of drug therapies. Diabetic sub-
jects were more likely to receive ACEI, angiotensin recep-
tor blockers, and statin therapy compared to-non diabetic
CKD subjects, and 32% less likely to receive NSAIDs (P <
.0001).
eGFR serum creatinine in mgl dl age =× × ×
−− 186 3 0
1 154 0 203 .( / ) (
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Prevalence of CKD documentation
Table 2 describes baseline patient characteristics by CKD
documentation. Only 14.4% of subjects, with a baseline
GFR between 10- 60 ml/min/1.73 m2 had a CKD diagno-
sis present at baseline. Subjects with an eGFR < 50 ml/
min/1.73 m2, male gender, hypertension, diabetes, coro-
nary artery disease, congestive heart failure, cerebrovascu-
lar and peripheral artery disease were significantly more
likely to be documented with CKD in the univariate anal-
ysis.
Subjects with CKD documentation were 61% more likely
to use an ACEI (P < .0001)), 67% more likely to use an
ARB (P = .0080), 27% more likely to use a statin (P =
.0014) and 37% less likely to use an NSAID (P < .0001)
compared to patients without CKD documentation.
Multivariate association between predictors and CKD 
documentation
After controlling for subject characteristics, coronary
artery disease and cerebrovascular disease were no longer
significant predictors of CKD documentation (Table 3).
Older age, lower eGFR, peripheral artery disease, conges-
tive heart failure, and statin use were significantly associ-
ated with physician documented CKD. Gender and
hypertension were found to be significant effect modifiers
of the association between diabetes and CKD documenta-
tion (P for interaction = 0.0053 and 0.0065, respectively)
therefore adjusted ORs for CKD documentation are pre-
sented by gender, hypertension and diabetes status (Fig-
ure 2). CKD documentation was more likely among male
and female patients with hypertension and/or diabetes.
Within each strata, CKD was more likely to be docu-
mented among men than women.
The prevalence of CKD documentation among CKD par-
ticipants with hypertension and diabetes were 30% in
men and 19% women (Figure 3). Male hypertensive
patients were four times more likely to be documented
with CKD than non-hypertensive/non-diabetic partici-
pants (adjusted OR [aOR], 4.75; 95%CI 3.60 to 6.27)],
while those with diabetes were two times more likely to be
documented with CKD than non-diabetics (aOR, 2.52;
95%CI 1.40 to 4.53). A similar trend was found among
women after adjustment, but the magnitude of the inter-
action between diabetes and hypertension was greater.
Female CKD patients with both diabetes and hyperten-
sion were seven times more likely to have a CKD diagnosis
documentation than non-hypertensive/non-diabetic par-
ticipants (aOR, 7.74; 95%CI, 5.58 to 10.72), while males
with diabetes and hypertension were five times more
likely to have a CKD diagnosis documentation than non-
hypertensive, non-diabetic males (aOR, 5.26; 95%CI 3.85
to 7.20).
Table 1: Characteristics of 10,266 KP Chronic Kidney Disease Enrollees and Univariate Associations With Type 2 Diabetes Status
Baseline 
Characteristics
Total Cohort N = 
10266 
(100) (% or SD)
Diabetic CKD N = 
2508 (24.43)(% or SD)
Non diabetic CKD N = 
7758 (75.56) (% or SD)
Odds Ratio (diabetic 
CKD vs non diabetic 
CKD)
P value
Mean age 
(continuous)
63.06 (13.43) 63.50 (11.63) 62.92 (13.96) NA 0.0386
Mean eGFR* 
(continuous)
48.81 (10.11) 46.04 (11.46) 49.57 (9.52) NA < .0001
Men 4155 (40.47) 1111 (26.74) 3044 (73.26) 1.23 (1.12-1.34) < .0001
Hypertension 7916 (77.11) 2297 (29.02) 5619 (70.98) 4.14 (3.56-4.81) < .0001
eGFR 50-59 5868 (57.16) 1220 (20.79) 4648 (79.21) 1.00 (Referent) -
eGFR 40-49 2593 (25.26) 657 (25.34) 1936 (74.66) 1.29 (1.16-1.44) -
eGFR 30-49 1142 (11.12) 367 (32.14) 775 (67.86) 1.80 (1.57- 2.07) -
eGFR 20-39 457 (4.45) 171 (37.42) 286 (62.58) 2.27 (1.86- 2.78) -
eGFR 10-19 206 (2.01) 93 (45.15) 113 (54.85) 3.13 (2.36- 4.15) < 0.0001**
Coronary artery 
disease
1335 (13.00) 451 (33.78) 884 (66.22) 1.70 (1.50-1.92) < .0001
Chronic heart 
failure
750 (7.31) 293 (39.07) 457(60.93) 2.11 (1.81-2.46) < .0001
Cerebrovascular 
disease
163 (1.59) 62 (38.04) 101 (61.96) 1.92 (1.39-2.64) < .0001
Peripheral artery 
disease
490 (4.77) 253 (51.63) 237 (48.37) 3.56 (2.96-4.27) < .0001
ACEI use 1500 14.61) 631 (42.07) 869 (57.93) 2.66 (2.37-2.98) < .0001
ARB use 156 (1.52) 71 (45.51) 85 (54.49) 2.63 (1.91-3.61) < .0001
Statin use 1448 (14.10) 476 (32.87) 972 (67.13) 1.63 (1.45-1.84) < .0001
NSAID use 1213 (11.82) 228 (18.80) 985 (81.20) 0.68 (0.59-0.80) < .0001
*eGFR in ml/min/1.73 m2; ** P value for trendBMC Nephrology 2009, 10:25 http://www.biomedcentral.com/1471-2369/10/25
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Table 2: Univariate associations with CKD documentation
Baseline Characteristics With CKD Documentation
N = 1478 (14.40)
(% or SD)
Without CKD 
Documentation
N = 8788 (85.6)
(% or SD)
Odds Ratio 
(with vs without CKD 
documentation)
P value
Mean age (continuous) 62.84 (13.51) 63.10 (13.41) NA 0.4829
Mean eGFR* (continuous) 38.66 (13.04) 50.52 (8.41) NA < .0001
Men 876 (21.08) 3279 (78.92) 2.44 (2.18-2.73) < .0001
Hypertension 1397 (17.65) 6519 (82.35) 6.00 (4.77-7.54) < .0001
Diabetes 565 (22.53) 1943 (77.47) 2.18 (1.94-2.44) < .0001
eGFR 50-59 346 (5.90) 5522 (94.10) 1.00 (Referent) -
eGFR 40-49 372 (14.35) 2221 (85.65) 2.67 (2.29-3.12) -
eGFR 30-49 362 (31.70) 780 (68.30) 7.40 (6.27-8.73) -
eGFR 20-39 252 (50.14) 205 (44.86) 19.61 (15.84-24.3) -
eGFR 10-19 146 (70.87) 60 (29.13) 38.83 (28.21-53.46) < 0.0001**
Coronary artery disease 293 (21.95) 1042 (78.05) 1.83 (1.59-2.12) < .0001
Chronic heart failure 216 (28.80) 534 (71.20) 2.64 (2.23-3.13) < .0001
Cerebrovascular disease 38 (23.31) 125 (76.69) 1.82 (1.26- 2.64) 0.0011
Peripheral artery disease 151 (30.82) 339 (69.18) 2.83 (2.32-3.46) < .0001
ACEI use 300 (20.00) 1200 (80.00) 1.61 (1.39-1.85) < .0001
ARB use 34 (21.79) 122 (78.21) 1.67 (1.13-2.45) 0.0080
Statin use 248 (17.13) 1200 (82.87) 1.27 (1.09- 1.48) 0.0014
NSAID use 122 (10.06) 1091 (89.94) 0.63 (0.52- 0.77) < .0001
*eGFR in ml/min/1.73 m2, ** P value for trend, NA not appropriate
Sub-analysis of the impact of diabetes status on CKD doc-
umentation within each eGFR category was performed. In
nearly all strata, the presence of diabetes increased the
likelihood of CKD documentation.
Discussion
Our primary findings are that, among patients with an
eGFR 10-59 ml/min/1.73 m2, documentation of CKD
within a managed care organization is low (14.4%) and
that CKD documentation is associated with male gender,
increasing age, CKD severity, peripheral artery disease and
congestive heart failure. In addition, CKD was more likely
to be documented among patients with a combination of
hypertension and diabetes.
The prevalence of CKD documented in our analysis is sim-
ilar to the proportion of patients identified by their pri-
mary care physician as having CKD (13.9%) and reported
in the pre-intervention period of an educational program
performed at an outpatient family medicine practice [16].
Our findings suggest that CKD identification within a
managed care organization is as low as in the non-institu-
tionalized U.S. adult population. Indeed, studies assess-
ing self-reported physician diagnosed kidney disease
awareness among U.S. adults in the National Health and
Nutrition Examination Survey (NHANES) found that
CKD identification ranged from 2.9% (women with Stage
3 CKD) to 24.3% (individuals with a GFR of 15 to 59 ml/
min per 1.73 m2 and albuminuria) [8,11]. Differences in
the estimates reported from the NHANES study and our
current study are notable since we assessed physician doc-
umentation of CKD using claims diagnoses while the
NHANES study assessed self-reported CKD awareness by
participants.
We found that CKD documentation by providers
increased with the presence of hypertension or diabetes in
both genders, but was consistently and considerably
lower among women. While CKD was documented in
one third of men with hypertension and diabetes, less
than 20% of similarly affected women were documented
to have CKD. The gender difference in CKD identification
was even greater among participants without hyperten-
sion or diabetes, hypertension only, and diabetes only.
Previous findings suggest that women are less likely to be
Study Flow Chart Figure 1
Study Flow Chart.BMC Nephrology 2009, 10:25 http://www.biomedcentral.com/1471-2369/10/25
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aware of their CKD status, and our results extend these
findings by reporting that providers are less likely to rec-
ognize CKD among women with a reduced GFR com-
pared with men [8,11,17]. It has been suggested that
health care providers are prone to overlook CKD in
women who may have a serum creatinine value in the
normal range, due to decreased muscle mass, but have a
decline in GFR. Accordingly, the eGFR predictive equation
is recommended to estimate the level of renal function
from creatinine concentration [18].
We found that eGFR, hypertension, diabetes, congestive
heart failure, peripheral artery disease, statin use, and
older age were factors significantly associated with CKD
diagnosis documentation. CKD patients with hyperten-
sion and/or diabetes were more likely to be identified as
having CKD than were CKD participants without diabetes
or hypertension.
While current guidelines recommend the screening of
individuals with diabetes or hypertension for CKD,[6,19]
we found that patients with hypertension were more
likely be documented as having CKD. Reasons for the
greater impact of hypertension on CKD identification are
unclear. It is possible that the lack or small number of
endocrinologists within the HMO may delay CKD identi-
fication in diabetic enrollees, as other providers may not
be as aware of the American Diabetes Association Guide-
lines recommending that serum creatinine is measured
annually for eGFR in all adult diabetics [18]. The discrep-
ancy between the effect of hypertension and diabetes has
been reported in the general population, where a history
of hypertension, but not diabetes, significantly increases
the likelihood of CKD awareness by almost 3 times (aOR,
2.98; 95%CI, 1.39 to 6.39) [8].
Our study findings are consistent with previous observa-
tions that eGFR is a strong predictor of CKD identification
[8,11,20]. We found a significant trend of CKD documen-
tation with decreasing eGFR. Nevertheless, CKD docu-
mentation is only 6%, 14%, 31% and 50% among
enrollees with eGFR 50-59, 40-49, 30-39 and 20-29 ml/
min/1.73 m2, respectively. One third of enrollees with an
eGFR of 10-19 ml/min/1.73 m2 were not documented as
having CKD. This finding suggests CKD identification is
poor at both early and advanced stages of CKD.
Although age is a key predictor of CKD, we found that
CKD documentation decreased with age [21]. A major
obstacle in the identification of CKD with increasing age
may be the reliance on serum creatinine measurements as
an estimation of eGFR,[22] resulting in an under-identifi-
cation of CKD among the elderly. Our finding is sup-
ported by a recent study of Veterans Administration
outpatients 70 years and older, revealing that among CKD
Stage 2, 3, and 4 patients, the diagnosis of CKD was doc-
umented among only 1.2%, 20%, and 74.6% of patients,
respectively, with nephrology consults requested in fewer
than 5% of patients [23].
Finally, we found that statin medication use was predic-
tive of CKD documentation, even after adjustment for dia-
betes, hypertension, and cardiovascular disease. While the
predictive nature of statin use has not been previously
reported in relationship to CKD care, statin use may be a
surrogate marker of better quality of care, and has been
proposed as a source of treatment bias in the evaluation of
cardiovascular disase outcomes [24,25]. Interestingly,
ACEI use was not significantly associated with CKD iden-
tification after adjustment. Although ACEI has been
shown to reduce the rate of progression of CKD in both
diabetics and non-diabetics, [26-28] and although it is
identified that ACEI is more effective when instituted early
Table 3: Predictors of Chronic Kidney Disease Documentation in multivariate analysis
CKD Diagnosis Documentation Prediction Variables aOR of CKD documentation (95%CI) P value
Age at baseline (by 1 year of increase) 0.98 (0.98-0.99) < .0001
eGFR** 40-49 vs 50-59 2.55 (2.17-3.00) < .0001
eGFR 40-39 vs 50-59 7.39 (6.19-8.82) < .0001
eGFR 20-29 vs 50-59 18.37 (14.59-23.13) < .0001
eGFR 10-19 vs 50-59 35.33 (25.14-49.65) < .0001
Coronary artery disease 1.05 (0.87-1.25) 0.5882
Cerebrovascular disease 1.22 (0.80-1.85) 0.3477
Peripheral artery disease 1.51 (1.19-1.93) 0.0008
Chronic heart failure 1.44 (1.18-1.78) 0.0004
Statin use 1.22 (1.03-1.46) 0.0194
ACEI use 0.97 (0.82-1.15) 0.7673
NSAID use 0.81 (0.65-1.01) 0.0705
*Significant interactions in multivariate model were found between type 2 diabetes and gender with respect to CKD documentation (p value for 
interaction = 0.0053), as well as between type 2 diabetes and hypertension (p value for interaction = 0.0065) with respect to CKD documentation.
**eGFR in ml/min/1.73 m2BMC Nephrology 2009, 10:25 http://www.biomedcentral.com/1471-2369/10/25
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in the course of the CKD, ACEI treatment prevalence in
our cohort of CKD HMO enrollees was poor, as described
in other settings [29-31]. Furthermore, the prevalence of
ACEI use was only slightly higher among enrollees with
identified CKD than unidentified CKD. This suggests that
factors other than CKD identification contribute to the
low ACEI treatment prevalence observed among CKD
patients. Contrary to a previous report which showed that
CKD diabetic patients are not more likely to be prescribed
ACEI than those without diabetes,[30] in our analysis,
diabetics with CKD were nearly three-fold more likely to
be prescribed ACEI than non-diabetic CKD members,
confirming the finding of a previous HMO-base analysis
[31].
This study has several limitations. CKD was determined
on the basis of ICD 9 codes, leading to the possibility of
misclassification. Although previous validation studies
suggest that ICD-9 coding for disease identification has
sensitivity and specificity greater than 80%,[32,33] others
suggest lower performance and methodological issues
[34,35]. However, our observations that CKD documenta-
tion increased with lower eGFRs, and NSAID prescription
use was lower among enrollees with identified CKD, sug-
gest that the use of ICD-CM codes is valid. Second we used
ICD9-codes from event encounters which list only the
presenting condition for that visit. Thus, in the absence of
patient medical record abstraction, the estimate of CKD
diagnosis documentation that we report may be an under-
estimate of the true CKD identification in this population.
Third, we lacked data on patient race, and instead, used
geocoding for estimating race, which then was used for
the eGFR calculation. The validity of geocoding for esti-
mating race has been recently explored. Fremont et al.
reported that among 17,500 Medicare enrollees, 92%
were successfully identified as either black or other using
geocoding [36]. In another study, Glaeser et al also found
that geocoding can produce accurate estimates of black
race [37]. Experts in health services research suggest that
in the absence of direct method, the use of block census
geocoding is appropriate [38]. To calculate eGFR in the
absence of race, others have assumed that no patients
were black or alternatively, have used census data to
impute an average constant proportion of black in their
study population [9,20]. To test the impact of estimating
race using geocoding, we performed all our analysis using
eGFR without race and it did not meaningfully change the
nature and magnitude of the predictors. Since our cohort
is limited to Kaiser Permanent Georgia, our results may
not be generalizable to persons in other geographic set-
tings. Although this study has limitations, it examines a
large cohort of CKD patients. Finally, because our analy-
Adjusted Odds Ratio of Chronic Kidney Disease Documentation* Figure 2
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ses applied to CKD members identified between January
1, 1999 through January 1, 2006, it is possible that current
(2009) documentation of CKD is higher as awareness of
CKD in the general population and/or among medical
professionals may have increased thanks to advertising
and published reports.
Conclusion
In conclusion, among a large cohort of HMO members,
the prevalence of CKD diagnosis documentation is low,
and similar to that of the general population. Several
important predictors are associated with CKD diagnosis
documentation among patients with an eGFR 10-59 ml/
min/1.73 m2, including age, male gender, severity of renal
disease, hypertension, diabetes, congestive heart failure,
peripheral artery disease, and statin use.
Emphasis on early detection of kidney disease among
HMO members may slow the progression and complica-
tions of CKD, therefore strategies aimed to increase CKD
early detection are warranted [19,39,40]. In addition,
efforts that include focusing on patients in whom CKD
identification is poor, such as women, and increasing the
use of medications associated with a reduction in CKD
progression may limit the number of patients who experi-
ence morbidity and mortality related to advanced chronic
kidney disease.
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